Royal Bank of Canada
ADIL

Royal Bank of Canada’s Adial Pharmaceuticals ADIL Stock Holding History

Royal Bank of Canada’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed – – 6787
2024
Q2 		$0 Hold
1
– – ﹤0.01% 6977
2024
Q1 		$0 Sell
1
-1
-50% -$37 ﹤0.01% 6946
2023
Q4 		$0 Hold
2
– – ﹤0.01% 7054
2023
Q3 		$0 Hold
2
– – ﹤0.01% 7025
2023
Q2 		$0 Buy
+2
New +$362 ﹤0.01% 7199
2022
Q4 		– Hold
0
– – – 7168
2022
Q3 		– Hold
0
– – – 7395

Other funds holding ADIL

MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
1IA
1620 Investment Advisors Plymouth, Massachusetts $161M AUM 30.15% 1-Year Est. Return
RWML
RAFFA WEALTH MANAGEMENT, LLC Washington, District of Columbia $793M AUM 13.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada's ADIL Position: Q3 2024 in Review

Royal Bank of Canada sold out of Adial Pharmaceuticals (ADIL) in Q3 2024, closing a stake of 1 share.

Royal Bank of Canada first reported a position in ADIL in Q2 2023 and held it in 5 quarters. The position peaked at $0 in Q2 2024. 12 funds tracked by Wall St. Rank hold ADIL as of Q3 2024.

  • Royal Bank of Canada reported no remaining Adial Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 1 Adial Pharmaceuticals share in Q3 2024.
  • Royal Bank of Canada first reported a position in Adial Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Royal Bank of Canada's Adial Pharmaceuticals position peaked at $0 in Q2 2024.
  • 12 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.